Teva Pharmaceutical Industries’ board of directors agreed to take a 50 percent pay cut.

Mylan NV raised the lower end of its 2017 forecasts as the U.S. drugmaker expects to benefit from the earlier-than-expected approval of its copycat of Teva’s blockbuster multiple sclerosis treatment Copaxone.

Mylan NV said that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability in 2017 and 2018.

Shares of Teva Pharmaceutical Industries were in a freefall after the company posted disastrous second-quarter 2017 earnings and announced it intended to terminate thousands of employees as management looks to shutter several manufacturing facilities.

Support Info-Go, the leading provider of health condition event listings, wants cancer patients to know they are not alone and celebrate independence from their condition with the launch of Cancer-Go.

The number of new drugs approved for sale in United States and Europe has bounced back in 2017, suggesting a marked slowdown in 2016 was an aberration.

What if a single smartphone app could help solve the enigma of multiple sclerosis (MS) and move new treatments ahead at lightning speed? That was the bold idea that led Keck Medicine of USC neurologist Daniel Pelletier, MD, professor of neurology at the Keck School of Medicine of USC and division chief of the Neuro-Immunology and USC Multiple Sclerosis Center, to develop myMS – the world’s first smartphone app capable of collecting large amounts of clinical, imaging and genetic data for people with MS. Enrollment is now under way for a pilot study of the app.

Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.

Ardsley, NY-based Acorda Therapeutics announced significant restructuring, including laying off approximately 20 percent of its 597 employees.

Investors and biotech insiders are waiting during March 2017 for the U.S. Food and Drug Administration to rule on six therapies that will impact the bottom line of the developers, according to an analysis by RTT News.